Laden…
Synapedia is an independent knowledge project about psychoactive substances and harm reduction. If the platform helps you learn something new, you can support its development.
Every bit helps keep the project alive.
N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
Zolpidem is a fast-acting hypnotic from the imidazopyridine group, primarily used for the short-term treatment of sleep disorders. It acts as an agonist at the benzodiazepine binding site of the GABA-A receptor, thereby enhancing the inhibitory effect of GABA in the central nervous system. Due to its mechanism of action, it may have potential for dependence and should only be used under medical supervision.
Translation in progress
This section is currently being translated. Content will be available soon.
View German version →Receptor Targets
Mechanism of Action
Designations
IUPAC: N,N-dimethyl-2-[6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl]acetamide
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Effects & Pharmacology — Translation in progress
This section is being translated. Content is available in German.
View in German →Total duration 6-8 hours
Peak
1-2 hours
Onset
15-30 minutes
Total duration
6-8 hours
After effects
2-4 hours
Start low. Individual sensitivity varies.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, and pre-existing conditions significantly affect outcomes.
Risks
Evidence
strong
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Some combinations can be dangerous. Research before combining substances.
Schwere ZNS-Depression und paradoxe Verhaltensweisen
Zolpidem ist ein α1-selektiver GABA-A-Agonist (Z-Drug). Ethanol potenziert den gleichen Rezeptortyp. Die Kombination führt zu überadditiver Sedierung, anterograder Amnesie und erhöhtem Risiko für paradoxe Verhaltensweisen (Schlafwandeln, unkontrolliertes Essen, Fahren im Schlaf).
Additive Atemdepression und Sedierung
Zolpidem ist ein Imidazopyridin-Hypnotikum mit selektiver Wirkung an der α1-Untereinheit des GABA-A-Rezeptors. Die α1-Selektivität bewirkt Sedierung und Hypnose, reduziert aber nicht die atemdepressive Wirkung. In Kombination mit Opioiden addiert sich die Atemdepression über komplementäre Mechanismen (GABA-A + μ-Opioid). Die Atemdepression tritt bevorzugt im Schlaf auf — dies erschwert die Erkennung. Zolpidem wird häufig bei gleichzeitiger Opioidtherapie verordnet (Schmerzpatienten mit Schlafstörungen), was die klinische Relevanz erhöht.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.